Sunshine Biopharma (SBFM) Net Cash Flow (2010 - 2026)

Sunshine Biopharma's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• Quarterly Net Cash Flow fell 40.27% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.0 million (up 76.39% YoY) and the FY2025 annual result came in at -$1.4 million, up 74.49% from the prior year.
• Net Cash Flow was -$2.2 million for Q1 2026 at Sunshine Biopharma, down from -$941715.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $28.5 million in Q2 2022 and bottomed at -$19.0 million in Q4 2022.
• A 5-year average of $260798.6 and a median of -$941715.0 in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 41959.55% — and 2024, when it slumped 25270.25%.
• Sunshine Biopharma's Net Cash Flow stood at -$19.0 million in 2022, then jumped by 84.23% to -$3.0 million in 2023, then soared by 36.95% to -$1.9 million in 2024, then surged by 50.04% to -$941715.0 in 2025, then plunged by 131.13% to -$2.2 million in 2026.
• Business Quant data shows SBFM's Net Cash Flow at -$2.2 million in Q1 2026, -$941715.0 in Q4 2025, and -$770559.0 in Q3 2025.